Jacobs Levy Equity Management, Inc Lyell Immunopharma, Inc. Transaction History

Jacobs Levy Equity Management, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.3 - $3.01 $3,380 - $7,825	2,600 Added 9.1%	31,184 $45,000
Q1 2024 May 15, 2024	BUY	$1.71 - $3.07 $48,878 - $87,752	28,584 New	28,584 $63,000
Q3 2023 Nov 16, 2023	BUY	$1.45 - $3.35 $327,386 - $756,376	225,784 Added 226.75%	325,359 $478,000
Q2 2023 Aug 14, 2023	SELL	$1.89 - $3.86 $2.93 Million - $5.99 Million	-1,552,223 Reduced 93.97%	99,575 $316,000
Q1 2023 May 15, 2023	BUY	$1.97 - $3.58 $3.25 Million - $5.91 Million	1,651,798 New	1,651,798 $3.9 Million

121

142M

18.1K

200

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $151M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.